DTC
FATE icon

Deep Track Capital’s Fate Therapeutics FATE Stock Holding History

Deep Track Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,572,607
Closed -$19.5M – 71
2024
Q3 		$19.5M Hold
5,572,607
– – 0.62% 45
2024
Q2 		$18.3M Hold
5,572,607
– – 0.55% 45
2024
Q1 		$40.9M Buy
+5,572,607
New +$34.5M 1.17% 34
2022
Q4 		– Sell
-1,311,113
Closed -$29.4M – 65
2022
Q3 		$29.4M Sell
1,311,113
-706,892
-35% -$20.4M 1.35% 26
2022
Q2 		$50M Buy
2,018,005
+18,005
+0.9% +$497K 3.29% 10
2022
Q1 		$77.5M Buy
2,000,000
+1,581,963
+378% +$61.3M 4.97% 6
2021
Q4 		$24.5M Buy
+418,037
New +$23.7M 1.73% 21

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Deep Track Capital's FATE Position: Q4 2024 in Review

Deep Track Capital sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 5,572,607 shares — an estimated $19.5M sold.

Deep Track Capital first reported a position in FATE in Q4 2021 and held it in 7 quarters. The position peaked at $77.5M in Q1 2022. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Deep Track Capital reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Deep Track Capital sold 5,572,607 Fate Therapeutics shares in Q4 2024, an estimated $19.5M.
  • Deep Track Capital first reported a position in Fate Therapeutics in Q4 2021 and held it in 7 quarters.
  • Deep Track Capital's Fate Therapeutics position peaked at $77.5M in Q1 2022.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Deep Track Capital's 13F filing for Q4 2024, filed 14 Feb 2025.